C-4XZKVaxxinity (website removed all info intentionally*)
COVID booster
clearingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-4XZK
C-4XZKC-4XZKCOVID booster
0-100 chain-logic scale · 15 dimensions · scored on public evidence
We get to hear from a lot of smart people with incredible ideas on this show, but it's extra exciting when they also have a world-changing vision, and our guest today has just that. On this week's episode we're talking with Mei Mei Hu, CEO and Co-Founder of Vaxxinity, which trades under the symbol VAXX. Mei Mei is also a member of the Executive Committee of United Biomedical, and has overseen the launch of one of the first antibody vaccines in the world, and the successful spin out of five companies, including Vaxxinity's IPO in 2021. She currently leads an active pipeline of chronic disease immunotherapeutic candidates, including for Alzheimer's, Parkinson's, migraine, hypercholesterolemia, and variant inclusive COVID booster. Mei Mei has been named to the Time 100 Next List, Fortune 40 under 40, and is a member of the Young Global Leaders of World Economic Forum. She holds a BA from University of Pennsylvania and a JD from Harvard Law School. We recorded this episode with Mei Me
A new class of vaccines may hold the key to preventing Alzheimer’s, Parkinson’s and other chronic diseases. On this week’s episode of Alternatively Speaking, Vaxxinity’s Co-founder and Executive Chairman, Lou Reese, joins our hosts for a deep dive on the company’s work to develop these life changing treatments.
Today, our host sat down with Lou Reese, co-founder and Vice Chairman of Vaxxinity, a purpose-driven biotechnology company pioneering a new class of medicines aimed at disrupting existing treatments for chronic diseases. Founded in 2014 alongside his wife and CEO, Mei Mei Hu, Vaxxinity is at the forefront of developing “next generation” vaccines for chronic conditions such as Alzheimer’s, Parkinson’s, heart disease, and migraine. Lou Reese also serves on the Executive Committee of United Biomedical, Inc. (UBI), a multinational biopharmaceutical organization focused on developing diagnostics and immunotherapeutics for global health improvement. Lou was a director at ShenLian Biotech, one of the largest animal health companies in China, and co-founded an investment firm with ventures spanning real estate, energy, hospitality, and life sciences. Podcast Highlights: Introduction & Lou Reese’s Background (3:00): Lou’s journey and his mission to eliminate global suffering. Synthetic Peptid
Do the secrets to combatting disease already reside within our own bodies? We rely heavily on vaccines for serious disease, but this week's guest talks about the power of unleashing our own immune system. Lou Reese is the Board Chair and Co-Founder - along with his wife Mei Mei - of Vaxxinity, a company that focuses on active immunity medicines. I had the opportunity sit down with Lou for a pop-up podcast at a recent Abundance Platinum conference hosted by Peter Diamandis, at which Lou and I were both speaking. You'll notice the hotel ballroom curtain background. In this episode, we connect the dots between medical science and social science, discussing not just the incredible breakthroughs that Lou and his team are working on, but also finding your purpose and even setting examples for your children. To follow the work at Vaxxinity: https://x.com/vaxxinity - - - Follow me on my platforms here: Web: www.pilotinghealth.com Instagram: https://www.instagram.com/drbobhariri/ X: https
Mei Mei Hu, CEO of Vaxxinity, discusses the company's approach to targeting a wide variety of chronic diseases such as Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia, as well as their COVID-19 booster vaccine. Vaxxinity aims to utilize its unique synthetic peptide platform technology to bring the convenience, efficiency, and cost-effectiveness of vaccines to the treatment and prevention of chronic diseases -- making critical medicines available to all. For more information on Vaxxinity visit https://vaxxinity.com. #ChronicDiseaseVaccines Mei Mei is Chief Executive Officer and Co-Founder of Vaxxinity and is also a member of the executive committee of United Biomedical, Inc. She has overseen the launch of one of the first endobody vaccines in the world and the successful spin-out of five companies, including Vaxxinity’s IPO on NASDAQ. She currently leads an active pipeline of chronic disease immunotherapeutic candidates including for Alzheimer’s, Parkinson’s, and hypercho
In this second fireside chat, Wendy Weidner, ADI's Head of Research and Publications, alongside Andrea Pfeifer of AC Immune SA and Mei Mei Hu of Vaxxinity, answer audience questions around current and future progress for vaccines, for Alzheimer’s disease and dementia. 00:00:00 Wendy Weidner opens up the webinar 00:03:15 Wendy introduces Andrea Pfeifer, CEO, Co-founder and Director of AC Immune SA and Mei Mei Hu, CEO and Chief Executive of Vaxxinity. 00:04:05 "How are these vaccines [for Alzheimer's disease and dementia] developed and how do they work?" 00:11:49 "What does it mean when a vaccine is 'fast tracked' by the United States Food and Drug Administration? What does it mean for your [AC Immune and Vaxxinity] vaccine and vaccines in general?"' 00:14:40 "Are these vaccines only for people with Alzheimer's disease or could they be applied wider [for other types of dementia and Down Syndrome]?" 00:19:50 "In Africa, people tend to have a later diagnosis. Do you still see the bene
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic candidate, is designed to assess the safety, tolerability, immunogenicity, and pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering in subsequent clinical trials.
#short #shortsvideo #shortvideo #biotech #biotechnology #science #scienceandtechnology #health #healthcare
#short #shortsvideo #shortvideo #biotech #biotechnology #science #scienceandtechnology #health #healthcare
In this episode, Lou and Peter discuss work-life integration, the issues with modern medicine, making life-changing drugs accessible to the world, and the mindset that has made Lou Reese successful. Lou Reese is the Co-Founder and Executive Chairman of Vaxxinity; a company focused on providing accessible cures to chronic diseases such as Parkinson’s, Alzheimer’s, Covid-19, and more. Learn more about Vaxxinity: https://vaxxinity.com/ This episode is brought to you by Levels: real-time feedback on how diet impacts your health. https://levels.link/peter Consider a journey to optimize your mind and body by visiting http://mylifeforce.com/peter Read the Tech Blog: https://www.diamandis.com/blog Timestamps 00:41 - 01:39 Intro 01:40 - 05:54 It's Not A Life/Work Balance, It's About A Life/Work Integration. 05:55 - 15:50 How Can You Stay Present In Life? 17:41 - 26:49 Did Sam Bankman-Fried Know What He Was Doing? 26:50 - 33:11 You Can't Bet Against Elon Musk 33:12 - 35:11 What's
There's big money to be make in drug development. But is that necessarily a good thing? Pharmaceutical companies capitalize on years of R&D work with exclusive patents. Approved drugs typically commercialize in developed markets that can support higher pricing through mature insurance reimbursement networks. Yet serious diseases don't only occur in the developed world. Billions of people in developing economics need treatments as well. And they're often not able to afford the hundreds of thousands of dollars it costs for innovative approaches such as CRISPR gene editing or CAR-T gene therapy. There's currently an unmet market need for treating serious chronic conditions like Alzheimer's Disease in a way that isn't prohibitively expensive. And sometimes, it's worth veering from the herd and thinking about big problems in an entirely new way. In today's 7investing podcast, 7investing lead advisors Simon Erickson and Dana Abramovitz chat with Mei Mei Hu, the co-founder and CEO of Vaxx
Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On this week's Business of Biotech podcast, Mei Mei joins me to share Vaxxinity's strategy, what "democratization" and "revolution" really_mean, why traditional vaccines and biologic therapies are converging to form the "third biologic revolution," and a whole lot more. #businessofbiotech #biopharma #biotech #cytiva http://cytiva.com/emergingbiotech Audio version available here: https://www.bioprocessonline.com/doc/what-s-a-biologic-revolution-with-vaxxinity-s-mei-mei-hu-j-d-0001 Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4 Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA Googl
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in healthy adults.
The shares of the clinical-stage biotech Vaxxinity (NASDAQ:VAXX) have recorded the biggest intraday gain on Friday since its IPO late last year after the company’s top executives disclosed multiple insider purchases. They include Vaxxinity’s (VAXX) Founder and Chief Executive Officer Mei Mei Hu and the Executive Chairman, Lou Reese.---https://seekingalpha.com/news/3829532-vaxx-stock-spikes-after-insider-purchases VAXX Stock targets: $7.02, $7.45, $7.61, $7.92, $8.01
This is a multicenter, international, randomized, active-controlled platform study with each sub-study designed to randomize subjects to receive a single injection with UB-612 or a comparator COVID-19 vaccine in 1:1 ratio.
Farshad Guirakhoo, Chief Scientific Officer, COVAXX & VAXXINITY speaks at the inaugural Vaccines Summit Ohio 2021 on March 1, 2021 Title of his talk: UB612- The First Multitope Covid-19 Vaccine Entering Ph2 Trials For more information about the summit and for the upcoming Vaccines Summit Boston 2021, please click on the link below: https://biogatesc.com/events/va-cc-in-e/
This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.
OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets You need to enable JavaScript to run this app.
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock | VAXX Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All S
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Episode 64: Taking a Shot: Chronic Disease Prevention and Vaccine Technology with Mei Mei Hu, Vaxxinity | ICR Skip to main content ICR homepage toggle navigation menu About Team What We Do toggle dropdown Sectors Healthcare Technology Consumer Business & Professional Services Financial Services Real Estate & Hospitality Industrials Energy & Clean Technology Transportation & Logistics Gaming, Sports, Media & Entertainment Crypto, Digital Assets & Blockchain Technology Services Corporate Communications & PR Investor Relations IPO & Capital Markets Advisory Crisis &
Challenging conventional thinking with Mei Mei Hu Therapeutic Technology Infection Global Health Events >> Get Our Newsletters Select Page Challenging conventional thinking with Mei Mei Hu by Charlotte Kilpatrick | May 11, 2023 | Technology | 0 comments In this interview we meet Mei Mei Hu, CEO and Co-Founder of Vaxxinity. She joined us at the Congress to explore the ideas of using vaccines to tackle chronic diseases and what supply and access lessons we have learnt. We were thrilled to catch up with her about her vision for “putting the tech in biotech” and democratising health. W
%PDF-2.0 %���� 417 0 obj >stream x�+��| endstream endobj 391 0 obj >stream H��Smo�0��_q c�8~��HӤ�����ּH�>���"��*���9� s L�DJ���=�swnl�ׇ~w���pv��}��|���*o��� �6o��VZS�t��> ��LU�@�~�o � _��_t]�=@n��z�q�_��n���tIn-�>����LP���Sڇ$��~v�|����J��J �����d�r��� ��܁^;}�I;� ��eL�݀[`�wx��+�`XIq�`�� � ����%��d��MI� �%��h���`�)�CH�h�ov0y����%��e� il�;���4n�u�� c7���iCc�w�$�nd�:$t�O�ѐkI�,}���O"M+%�!�/Սs��e�b=%0����iK���p��9�� endstream endobj 392 0 obj >stream H��SQO�0~ﯸG�T���"!�, �*b�x�V*m��� ��;�'����}�r���VZG�����"u �4�B��,� �#Vh@�ڢ� v(݅����Cs9�5��f�����S�XE``
With claims of potential Alzheimer’s edge, Vaxxinity squeaks out $78M IPO - MedCity News Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Newsletter Signup Send Tips Webinars eBooks Open navigation MedCity News Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search BioPharma, Pharma With claims of potenti … drove a T-cell response. However, Vaxxinity’s emergency use authorization application in Taiwan was turned down by regulators there, a decision the company is appealing. The peptide technology underpinning Vaxxinity was initially developed within United Biomedical Inc. (UBI), a privately held biotech company with roots stretching back more than 35 years. UBI initially developed its peptide vaccine technology for animals, and the company has refined it over the past two … tion totaling $89.4 million. That capital, combined with the IPO proceeds, will fund development of the pipeline. About $90 million is set aside for the company’s chronic disease drug candidates, primarily the completion of Phase 2b testing of Alzheimer’s candidate UB-311. The cash will also be used to bring the preclinical programs in the pipeline through Phase 1 development. Between $15 million to $20 million is planned for the company’s Covid-19 candidate
Vaxxinity Inc (VAXX) Stock, Price, News, Quotes, Forecast and Insights | MSN Money Popular ASX ▼ -0.19% BTC ▼ -0.20% USDAUD ▲ +0.16% ETH ▼ -0.33% BNB ▼ -1.39% DJI ▼ -0.09% CBA ▼ -0.42% ADA ▼ -2.14% PLS ▼ -6.32% WES ▲ +1.42% My watchlist BEGIN YOUR INVESTING JOURNEY Track and monitor your investments -- all in one place. Click on the icon to add stock to your watchlist. Suggested for you ASX Ltd ASX 51.79 -0.19% Bitcoin BTC 87,017.91 -0.20% USD/AUD Australian Dollar 1.45 +0.16% Ethereum ETH 2,278.44 -0.33% BNB BNB 806.33 -1.39% DOW DJI
Louis Reese - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Louis Reese Executive Chairman at Vaxxinity, Inc. Louis Reese 's Executive Work History Current Executive Chairman , Executive Chairman Vaxxinity, Inc. 10-K/A on 04/29/2024 Vaxxinity, Inc. Past To view Louis Reese's complete executive work history, sign up now Education M.B.A., Columbia University University of Pennsylvania
SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * Guirakhoo Farshad (Last) (First) (Middle) C/O VAXXINITY, INC 1717 MAIN ST, STE 3388 (S … ur-year time-vesting schedule, with 25% vesting on the first anniversary of the grant date] and the remainder vesting in equal installments each month during the remainder of the vesting period. Remarks: /s/ Rene Paula, attorney-in-fact for Farshad Guirakhoo 11/15/2021 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see In
Our Publications - Vaxxinity --> Our Science Our Platform Our Publications Our Lab News News Releases OUR PUBLICATIONS PUBLICATIONS Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial Alexander Rumyantsev, Lixia Wang, Shixia Wang, Tracy Kemp, Alana Wriggins, Amy Burks, Danielle Fisher, Katie Brokke, Amy Fix, Susan Hensley, Maggie Lewis, Ray Zhub, Kate Wang, Carolyn Shasha, Giulia Piccinic, Alessandro Manentic, Emanuele Montomolic, Rodrigo DeAntonio, Xavier Saez-Llorens, … one releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy. READ PUBLICATION UBITh “Vaccine” (2005) Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. READ PUBLICATION UB-311 Preclinical “Vaccine” (2007) Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. READ PUBLICATION UB-311
#vaxxinity #covid19 | Farshad Guirakhoo, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Coo
CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants Desktop Navigation Loading... Mobile Navigation Loading... Mobile Search Loading... Desktop Search Loading... COVID-19 News CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants CEPI 6th April 2022 Share Facebook LinkedIn X April 6, 2022; OSLO, Norway and DALLAS, USA: The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunot … of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity's next generation UB-612 COVID-19 vaccine candidate as a heterologous — or ‘mix-and-match' — booster dose. CEPI will provide up to $9.25m in funding. The Phase 3 trial, which began in the US earlier this year, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concer
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - ExecEdge Tech Edge PE Edge Research RSAC San Francisco Pax8 Beyond Now Reading: Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director Exec-Edge Full Article 40 second read Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director 1032 40 second read Peter Powchik, M.D. By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it appointed Peter Powchik, M.D. as Executive Vice President, Global Scientific Director overseeing its scientific direction and lead development efforts. Powchik was previously Senior
News - Vaxxinity --> Our Science Our Platform Our Publications Our Lab News News Releases News News Load More Sorry! No News Found. 2622 Commerce St., Dallas, TX 75226 Copyright © 2026 Vaxxinity
Posts with replies by Bloom Science (@BloomScience) / X Log in Sign up Bloom Science @BloomScience Bloom Science is a clinical-stage, central nervous system (CNS) company developing novel therapeutics through the #GutBrainAxis for neurological diseases. San Diego, CA bloomscience.com Joined May 2018 333 Following 164 Followers Posts Replies Media
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Res
Home - Vaxxinity --> Our Science Our Platform Our Publications Our Lab News News Releases Vaxxinity's COVID Booster Succeeds in Ph3 Best-in-class, long-lasting, well tolerated, cost-effective, and effective against emerging variants with no frozen cold chain, mRNA, or spike protein. Read Article in the Lancet Load More Read All News 2622 Commerce St., Dallas, TX 75226 Copyright © 2026 Vaxxinity
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida | VAXX Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S- … velopment of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option. “Our collaboration with the University of Florida will support the continued development of vaccines for neurodegenerative
Vaxxinity (VAXX) Stock News, Page 5 | StockTitan --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas Defense & Milit … timent End-of-Day 4.43% Tags clinical trial 04/06/2022 04:43 PM News CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants Rhea-AI Summary Vaxxinity, Inc. (Nasdaq: VAXX) has partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to co-fund a pivotal Phase 3 trial for its COVID-19 vaccine candidate, UB-612 . CEPI will provide $9.25 million to assess UB-612 as a heterologous booster for individuals previou
Mei Mei Hu, JD - Vaxxinity --> Our Science Our Platform Our Publications Our Lab News News Releases ABOUT US We are a global team united in the fight against human suffering. Introduction --> Mei Mei Hu, JD Chief Executive Officer Mei Mei is Chief Executive Officer and Co-Founder of Vaxxinity and is also a member of the executive committee of United Biomedical, Inc. She has overseen the launch of one of the first endobody vaccines in the world and the successful spin-out of five companies, including Vaxxinity’s IPO on NASDAQ. She currently leads an active pipeline of chronic disease immunother
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
%PDF-1.7 %���� 603 0 obj > endobj 636 0 obj >/Filter/FlateDecode/ID[ ]/Index[603 58]/Info 602 0 R/Length 144/Prev 1599063/Root 604 0 R/Size 661/Type/XRef/W[1 3 1]>>stream h�bbd```b``-��� ��1���L���k��O��$�"���lL`q-���`��`2 LJ�H�(��" �?D ��I?�x��� �����U"��A$�m��}`[�$#?�dQ���� L� L�@"@�L�g`8� ��� endstream endobj startxref 0 %%EOF 660 0 obj >stream h�b```a``Z���� �� ̀�@16�,��FE7m㌶H�2 լ�#Xn6,�*2^�v9�����?.��z[#��6�,�ޤ����4���=�n[��n�Ů ���Vg���}6�ֵ�� ];��ɑ{c����,I� �{�p㻷���=u��}���5�k� ���՝5��w�ieO{� f}?�hs�#\�9=��٢m /�Cu�;� ���M���x l�#�i[6�T�Wo[o� … LAB 60.392200 -23 38 PANTONE Cool Gray 10 C SPOT 100.000000 LAB 42.745098 0 -3 application/postscript DIALogo_576 Tony Lannutti proof:pdf xmp.did:c3ec3f04-7602-4362-9a46-a18797a62cfd xmp.iid:c3ec3f04-7602-4362-9a46-a18797a62cfd uuid:ad7bfbbf-c59c-6248-b0e3-f584afd56978 xmp.iid:7ae35b8b-4957-4d12-9d84-348369f5c8cf xmp.did:7ae35b8b-4957-4d12-9d84-348369f5c8cf uuid:ad7bfbbf-c59c-6248-b0e3-f584afd56978 proof:pdf saved xmp.iid:FED0ACD706DAE311A257F831BE9E476D 2014-05-12T15:30:50- … 77B8 2014-07-16T16:08:02-04:00 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:C71109902B0EE4119DC7CB2F7FFFB2A5 2014-07-17T23:28:19-04:00 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xm … 0B44 2014-07-22T07:36:42-04:00 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:724263c0-05dc-4d88-a970-1129545f4ab2 2014-08-27T15:19:25-05:00 Adobe Illustrator CC 2014 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:d1778c09-c249-465b-9e8d-c8ad9e293be6 2014-09-03T16:13:16-05:00 Adobe Illustrator CC 2014 (Macintosh) / converted from application/post … dobe Illustrator CC 2014 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:7ae35b8b-4957-4d12-9d84-348369f5c8cf 2017-02-15T15:32:54-05:00 Adobe Illustrator CC 2015.3 (Macintosh) / converted from application/postscript to
Vaxxinity Reports Fourth Quarter and Full-Year 2023 --> Accessibility: Skip TopNav Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates March 27, 2024 16:41 ET | Source: Vaxxinity, Inc. Vaxxinity, Inc. CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “2024 will prove to be a critical yea … 023 and Recent Corporate Updates Academic Collaborations & State of Florida Grant. In January 2024 Vaxxinity announced a collaboration with the University of Central Florida to conduct research funded by the state of Florida to further the development of our active immunotherapies against myostatin and activin A to prevent and mitigate muscle and bone wasting, well-known health challenges related to long-term spaceflight. These targets share biological mechanisms implicat
Our Pipeline - Vaxxinity --> Our Science Our Platform Our Publications Our Lab News News Releases Our Pipeline Our pipeline spans multiple therapeutic areas. We're developing a broad portfolio that has the potential to meaningfully improve millions of lives. Program (Target) Indication(s) Stage of Development Preclinical IND Phase I Phase II Phase III Marketed NEURODEGENERATION Preclinical IND Phase I Phase II Phase III Marketed UB-311 (Aβ) Alzheimer’s UB-311 (Aβ) Targets toxic forms of aggregated Aβ in the brain to fight Alzheimer’s. Phase 1, Phase 2a and Phase 2a LTE trials have shown UB-311
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates August 2, 2022 | 5 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced data … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine September 13, 2022 | 5 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunothe … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity to Present at Upcoming Investor Conferences in September 2022 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Vaxxinity to Present at Upcoming Investor Conferences in September 2022 September 1, 2022 | 2 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc., a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced that Mei Mei Hu, Chief Executive Officer of Vaxxini … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK) September 12, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has initiat … ew class of immunotherapeutic vaccines, today announced that it has initiated a rolling submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for conditional marketing authorization of its UB-612 COVID-19 vaccine as a heterologous boost to authorized primary series vaccines. DALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccin … ew class of immunotherapeutic vaccines, today announced that it has initiated a rolling submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for conditional marketing authorization of its UB-612 COVID-19 vaccine as a heterologous boost to authorized primary series vaccines. UB-612 is currently being assessed in a Phase 3 pivotal trial as a booster vaccine for subjects who have received primary immunization with mRNA, adenovirus ve … heart of Vaxxinity’s mission. Additionally, this authorization is a pathway to grant WHO emergency use listing (EUL), which would provide another option for getting UB-612 to countries through the COVAX program.” About UB-612 UB-612 is the first multitope subunit protein/peptide-based vaccine candidate for SARS-CoV-2, which is designed to activa
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients July 17, 2023 | 9 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. today announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigatio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Ther … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines July 25, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines. Summit i … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a … Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients March 7, 2024 | 6 min read Twitter LinkedIn Facebook Email Prin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida January 18, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced a collaboration with the University of Central F … ral Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases. “If humanity is to become a spacefaring species, solving fundamental problems relate … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine June 21, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Upon TFDA issuance of an EUA in Taiwan, an EUA will be issued in Paraguay and Vaxxinity will deliver 1MM doses of its CO … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine June 20, 2024 | 8 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines known as AIMs, announced that Nature Medicine has published groundbreaking exploratory … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
COVAXX and United Neuroscience Are Now Vaxxinity - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All New … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals COVAXX and United Neuroscience Are Now Vaxxinity April 1, 2021 | 5 min read Twitter LinkedIn Facebook Email Print COVAXX and United Neuroscience today announced the consolidation of their vaccine development efforts under the newly formed holding company, Vaxxinity, Inc. April 1, 2021 12:00 UTC … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Makers and Movers - Cold Chain 2021: Global Access and Distribution of COVID-19 Vaccine | 2021-01-08 | SupplyChainBrain Advertise Contact Us Supplier Directory SCB YouTube About Us Login Subscribe Logout My Profile Label LOGISTICS Air Cargo All Logistics Facility Location Planning Freight Forwarding/Customs Brokerage Global Gateways Global Logistics Last Mile Delivery Logistics Outsourcing LTL/Truckload Services Ocean Transportation Parcel & Express Rail & Intermodal Reverse Logistics Service Parts Management Transportation & Distribution TECHNOLOGY All Technology Artificial Intell … oving Robots Site-to-Site JLL Finds Perfect Warehouse Location, Leading to $15M Grant for Startup Robots Speed Fulfillment to Help Apparel Company Scale for Growth Visit Our Sponsors More From SCB Featured Content Video Library Think Tank Blog SupplyChainBrain Podcast Whitepapers On-Demand Webinars Upcoming Webinars Digital Offerings Digital Issue Subscribe Manage Email Preferences Newsletters Resources Events Calendar 2026 Event Coverage SCB's Great Supply Chain Partners
Vaxxinity, Inc. (VAXX) Latest News & Stock Updates - Page 1 Skip to main Stocks Options ETFs Crypto Bonds High-Yield Cash Account API Agents More About Us Learn Support Sign In Get Started About VAXX Options chain Market cap P/E ratio Earnings News Pre-market After-hours VAXX • News Stocks Vaxxinity, Inc. News VAXX Volume: 263 Vaxxinity, Inc. (VAXX) Latest News & Updates Explore latest Vaxxinity, Inc. (VAXX) News and Updates Stay updated on Vaxxinity, Inc. (VAXX) with the latest news, market trends, and key developments to support informed investing decisions. Start investing in Vaxxin … during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more. Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more. Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for i
EX-99.1 2 exhibit991.htm exhibit991 EXHIBIT   99.1 Vaxxinity   Appoints Dr.   Peter Powchik   to Board of   Directors DALLAS,   March   21,   2022 (GLOBE   NEWSWIRE)   -- Vaxxinity,   Inc. (Nasdaq: VAXX),   a U.S.   company   pioneering   the   development   of a   new class   of immunotherapeutic   vaccines   for chronic   diseases,   today   announced   that Peter   Powchik,   M.D. is   joining   its Board   of Directors   and   will
%PDF-1.7 4 0 obj (Identity) endobj 5 0 obj (Adobe) endobj 8 0 obj > stream x��} |T����{�f��� $6$� I�X �#��Ȃ! $@H �Z�Z+��Z��Z��.T-Rkm�`�U(Z�A+�PQ�VT {��9������ߧ��s����9gΜ�;��Ehd�Z:����� Q�(�[�S�+'��'�������3��.\s;�؆R�j�jZ����s"y�\��6{Dpԫ�І���,m� � & �����ҚU-�O� ��KW�]�gۀ|��(��P_S���T��@zn"����u�Onhj�����w)�D~�-�o]9a���2Q���͵5 ��[��ѡ?5�\ۢn������7շ�����9D�O�~�ʚ���ï�DS��M-ͫ��\Z�*d�������Co# ���0�D�Us��uaX���A@n������?>s�m�����? o)d8����3�(�s�o �|���2 T�7��q��%*/!�ߒ����oW�u�R��oQ����4���5�n���xt�[�9"���&PzT�i)�]���it?�żEU�uFҒL����q^� ,#-5ep�cPRb\T�-,4$(0���g�TEP�
Vaxxinity Appoints Peter Powchik to Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Oligonucleotide CMC and Regulatory Strategies - 2025 Archive About About the Event Attendee List Key Contacts Media Gallery Testimonials FAQ Agenda Search Agenda Programs Plenary Sessions Speaker Biographies Short Courses Breakout Discussions Brochures Networking Share Your Attendance Sponsor/Exhibit Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Sponsor/Exhibitor Prospectus Exhibit Floorplan Exhibit Kit Lead Generation Opportunities Travel Posters Poster Info Poster Titles Media Media Partners Newsroom Press Pass Register Individual Pricing Group Pricing On-
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates March 27, 2024 | 10 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today … 023 and Recent Corporate Updates Academic Collaborations & State of Florida Grant. In January 2024 Vaxxinity announced a collaboration with the University of Central Florida to conduct research funded by the state of Florida to further the development of our active immunotherapies against myostatin and activin A to prevent and mitigate muscle and bone wasting, well-known health challenges related to long-term spaceflight. These targets share biological mechanisms implicat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern February 11, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Vaxxinity, Inc. (Nasdaq: VAXX), today announced results from studies demonstrating the ability of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Vaxxinity | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Vaxxinity Website: Vaxxinity Business Area(s) Vaccines Peptides COVID-19 Alzheimer's Parkinson's Disease Description Their technology uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance&rdq
Vaxxinity gives update about potential Parkinson's vaccine UB-312 | Parkinson's News Today Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About Parkinson's Toggle menu: About Parkinson's What is Parkinson’s disease? Causes Diagnosis Symptoms Motor symptoms Nonmotor symptoms Types Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Exercise Diet Parkinson’s progression News Community Toggle menu: Community Awareness Month Perspectives The Bright Side – Jamie Askari The Impatient Pati
Vaxxinity Careers | Levels.fyi Download App Change Login Sign Up All Data By Location By Company By Title Salary Calculator Chart Visualizations Verified Salaries Internships H-1B Salaries Negotiation Support Compare Benefits Who's Hiring 2025 Pay Report Top Paying Companies Integrate Blog Press Google Software Engineer Product Manager New York City Area Data Scientist Explore By Different Titles Levels FYI Logo Salaries 📂 All Data 🌎 By Location 🏢 By Company 🖋 By Title 🏭️ By Industry 📍 Salary Heatmap 📈 Chart Visualizations 🗺️ Atlas 🔥 Real-time Percentiles 🎓 Internships 🛂 H-1B S … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured Jobs No featured jobs found for Vaxxinity Related Companies Coinbase Lyft Uber Square Tesla See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Featured Jobs No featured jobs found for Vaxxinity Related Companies Coinbase Lyft Uber Square Tesla See all companies ➜ Other Resources End of Year Pay Report Calculate Total Comp Request an AI summary of Levels
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Vaxxinity, Inc. (VAXX) Latest News & Stock Updates - Page 2 Skip to main Stocks Options ETFs Crypto Bonds High-Yield Cash Account API Agents More About Us Learn Support Sign In Get Started About VAXX Options chain Market cap P/E ratio Earnings News Pre-market After-hours VAXX • News Stocks Vaxxinity, Inc. News VAXX Volume: 263 Vaxxinity, Inc. (VAXX) Latest News & Updates Explore latest Vaxxinity, Inc. (VAXX) News and Updates Stay updated on Vaxxinity, Inc. (VAXX) with the latest news, market trends, and key developments to support informed investing decisions. Start investing in Vaxxin … Did Vaxxinity (VAXX) Stock Gain 80% Today? InvestorPlace • 04/29/22 CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants GlobeNewsWire • 04/06/22 Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates GlobeNewsWire • 03/24/22 Vaxxinity Appoints Dr. Peter Powchik to Board of Directors GlobeNewsWire • 03/21/22 Vaxxinity's COVID-19 Vaccine Candidate UB-612 Produces Hig … during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more. Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more. Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for i
Vaxxinity Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Vaxxinity Teams Vaxxinity Save Saved HQ Dallas 93 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Biotech Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled t
UB-313 / Vaxxinity UB-313 / Vaxxinity - LARVOL DELTA Home Next Prev 1 to 8 Of 8 Go to page 1 March 12, 2025 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Vaxxinity, Inc. | Active, not recruiting ➔ Completed Trial completion • CNS Disorders • Migraine • Pain Print Email More sharing Reddit StumbleUpon Delicious March 12, 2023 UB-313, an Investigational CGRP Vaccine for the Prevention of Migraine (AAN 2023) - "Interestingly, induced by UB-313 demonstrate a stronger potency ag … ts calcitonin gene-related peptide to fight migraines. Investigational new drug application (IND)-enabling studies are ongoing and we anticipate submitting a clinical trial application ('CTA') or an IND in 2022." Enrollment status • IND • P1 data • Preclinical • CNS Disorders • Migraine • Pain • Parkinson's Disease Print Email More sharing Reddit StumbleUpon Delicious 1 to 8 Of 8 Go to page 1 Copyright © 2026 - LARVOL. All Rights Reserved. | Privacy Policy | Contact Us
S-1 1 d142511ds1.htm S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on October 8, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vaxxinity, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 86-2083865 (State or other jurisdiction of incorpor … (“T-cell”) response. An emergency use authorization (“EUA”) application for UB-612 was denied by the Taiwan Food and Drug Administration (“TFDA”) in August 2021, but, in collaboration with our partner United Biomedical, Inc., Asia (“UBIA”), we are appealing that decision. At the same time, we are accelerating our development of our second COVID-19 product candidate, UB-612A, with pre-clinical data showing multifold higher neutralizing t … erent adjuvants. 4 Table of Contents We believe our Vaxxine Platform has application across a multitude of chronic and infectious disease indications beyond our existing pipeline. We also are developing additional product candidates that we believe may address significant unmet needs both within and beyond our current pipeline’s therapeutic areas. Our Team We have assembled an experienced group of executives with deep scientific, business and leadership expertise … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company, we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. To the extent that we continue to qualify as a “smaller reporting company,” as … use delays in the approval of a particular product candidate or rejection of an application for a particular product candidate. We have not obtained regulatory approval for any product candidate to date, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain
#podcast Mei Mei Hu, the CEO and... - Empowered Patient Radio Facebook Log In Empowered Patient Radio's Post Empowered Patient Radio January 9, 2024 · Shared with Public #podcast Mei Mei Hu, the CEO and Co-Founder of Vaxxinity, focuses on an approach to vaccines that aims to break immune tolerance to get the body to produce the antibodies to target self-antigens causing chronic conditions. Initial trials are being conducted to slow the progression or prevent the onset of Alzheimer's, Parkinson's, and hypercholesterolemia. Motivating this effort is the desire to democratize healt
Empowered Patient Podcast: Next-Generation Vaccines Breaking Immune Tolerance to Slow Progression or Prevent Onset of Chronic Conditions with Mei Mei Hu Vaxxinity TRANSCRIPT Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing He … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
COVAXX: Defeating COVID-19 <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1014361069129065&amp;ev=PageView&amp;noscript=1"> Speaking Overview Topics Longevity AI & Healthspan Meta-Trends Bold Thinking Abundance Testimonials Past Clients Schedule an Engagement Memberships Abundance360 Abundance Platinum Books Blog Podcast Our Singular Mission: Defeating COVID-19 Vaxxinity, a division of United Biomedical, is responding to the COVID-19 breakout in a manner that is consistent with our values by following the science and putting diagnost
Vaxxinity: transforming global healthcare with innovative vaccines Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Br … a limited number of targets that are really important to go after. If you could apply the same technology but to all chronic diseases, you’re talking about being able to expand your pipeline by 40 or 50 times.” To learn more about this topic: Here are some links to more articles on Vaxxinity’s pipeline, as well as other companies working on using vaccines to tackle hard-to-treat diseases. 6 new vaccines being developed for difficult-to-treat diseases (Labiotech.eu) Is a
Our CEO, Mei Mei Hu, is the #WomanoftheWeek on the PharmaVoice podcast Check out the full interview here: https://www.pharmavoice.com/news/woman-of-the-week-vaxxinity-mei-mei-hu-COVID-chronic-disease/627637/ Thank you Taren Grom for hosting this fascinating discussion! #democratizehealth #biologicrevolution | VAXXINITY
Mei Mei Hu, CEO and Co-Founder… - Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders - Apple Podcasts Search Home New Top Charts Search March 1, 2023 31 min Mei Mei Hu, CEO and Co-Founder of Vaxxinity – Taking a Shot: Chronic disease prevention and democratizing healthcare with vaccine technology Welcome to the Arena from ICR – Conversations with Today's Innovators & Business Leaders Play We get to hear from a lot of smart people with incredible ideas on this show, but it's extra exciting when they also have a world-changing vision, and our guest t
Woman of the Week: Vaxxinity's Mei Mei Hu | PharmaVoice Skip to main content CONTINUE TO SITE ➞ Don't miss the most important voices in pharma Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | BioPharma Dive Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercializatio
ICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena Podcast | ICR Skip to main content ICR homepage toggle navigation menu About Team What We Do toggle dropdown Sectors Healthcare Technology Consumer Business & Professional Services Financial Services Real Estate & Hospitality Industrials Energy & Clean Technology Transportation & Logistics Gaming, Sports, Media & Entertainment Crypto, Digital Assets & Blockchain Technology Services Corporate Communications & PR Investor Relations IPO & Capital Markets Advisory Crisis & Special Situations Governance,
Vaxxinity CEO Mei-Mei Hu: Advancing Vaccine Research and Health Equity Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Produ … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia … atter in our lives with Covid will hopefully lead the industry to find a way to apply them to a whole host of other illness, including chronic diseases. “If we can do that we are going to disrupt the way that medicine is delivered today with a focus on accessibility and prevention.” Opening big pharma to new discussions From speaking to Hu and observing her and Reese, her partner in industry and marriage, discussing their work in interviews, it is clear that they are not your
Whats A Biologic Revolution With Vaxxinitys Mei Mei Hu JD Get more Life Science Leader insight with our FREE newsletter. sign me up Log In or Subscribe Home Magazine Past Issues Digital Edition Articles Executive Interviews Companies To Watch Where Are They Now Industry Leader CEO Corner Ask The Board Key Topics Clinical Trials Finance-Funding Outsourcing Regulatory Research & Development Business of Biotech Podcast Podcast What's A Biologic Revolution? With Vaxxinity's Mei Mei Hu, J.D. Source: Bioprocess Online Vaxxinity CEO Mei Mei Hu, J.D. leads a company with some lofty ambitions. The
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ